EMD Serono is planning to construct a $70 million R&D facility on its existing campus in Billerica, Mass. Supporting research programs in oncology, immuno-oncology, and immunology, the 145,000-sf building will accommodate wet labs, offices, collaboration spaces, and a cafeteria. Designed to attain LEED and WELL certification, the project will provide a healthy and sustainable environment for approximately 400 employees. Completion is expected in 2021. EMD Serono is the biopharmaceutical business of Merck KGaA, based in Darmstadt, Germany.